Sodium Glucose Co-Transporter 2 Inhibitors and the Cardiovascular System: Current Knowledge and Future Expectations

Ioannis Boutsikos,Eleftherios Beltsios,Bastian Schmack,Ioannis Pantazopoulos,Dimitrios G Chatzis,Department Of Therapeutics, Alexandra General Hospital, National And Kapodistrian University Of Athens, Athens, Greece ,Department Of Cardiothoracic, Transplant And Vascular Surgery, Hannover Medical School, Hannover, Germany ,Department Of Cardiothoracic, Transplant And Vascular Surgery, Hannover Medical School, Hannover, Germany ,Department Of Emergency Medicine, Medical School, University Of Thessaly, Larissa, Greece ,School Of Medicine, European University Of Cyprus, Nicosia, Cyprus

doi:10.17925/hi.2023.17.2.5

Sodium Glucose Co-Transporter 2 Inhibitors and the Cardiovascular System: Current Knowledge and Future Expectations

Ioannis Boutsikos, Eleftherios Beltsios

Open Access

https://doi.org/10.17925/hi.2023.17.2.5

Copy DOI

Journal: Heart International	Publication Date: Jan 1, 2023
License type: CC BY-NC 4.0

#Sodium Glucose Co-transporter 2 #Improving Kidney Function + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Diabetic cardiomyopathy is a well-recognized clinical entity and reflects a complex relationship between metabolic substrates and myocardial function. Sodium glucose co-transporter 2 (SGLT2) inhibitors are antidiabetic agents that are found to exert multiple cardioprotective effects. Large clinical trials showed their beneficial effects on patients with heart failure, reducing the rates of rehospitalizations and improving kidney function. The aim of this review is to summarize the latest evidence in the literature regarding the multiple effects of SGLT2 inhibitors on patients across the spectrum of cardiovascular diseases.

Full Text